摘要
目的探讨根除消化性溃疡幽门螺杆菌的方法及疗效。方法采用药物联合方法治疗消化性溃疡伴幽门螺杆菌感染患者152例,将其分为研究组和对照组,各76例。对照组采用奥美拉唑+阿莫西林+克拉霉素三联药物治疗,研究组采用奥美拉唑+阿莫西林+克拉霉素+枸橼酸铋钾四联药物治疗,共治疗14 d,停药1个月后复查胃镜及幽门螺杆菌根除情况,观察两组患者的疗效。结果研究组患者溃疡康复达68例,对照组达55例;研究组幽门螺杆菌根除率为85.53%,明显高于对照组的71.05%(P<0.05)。结论采用奥美拉唑四联疗法根除消化性溃疡幽门螺杆菌疗效显著,且无不良反应发生,较质子泵抑制剂三联疗法疗效及患者康复情况更好,值得临床推广。
Objective To investigate the method and efficacy for the eradication of Helicobacter pylori in patients with peptic ulcer.Methods 152 cases of patients using drug combination therapy were divided into the study group and the control group,76 cases in each group. The control group used triple- combination： omeprazole ＋ amoxicillin ＋ clarithromycin,and the study group used quadri- combination： omeprazole ＋ amoxicillin ＋ clarithromycin ＋ colloidal bismuth subcitrate. Both groups were treated for 14 d,and after 2 months,the gastroscope and Helicobacter pylori as well as the efficacy were checked and observed in the two groups. Results The cured cases in the study group was 68 cases,and control group 55 cases; the eradication rate of helicobacter pylori in the study group was 85. 53%,which was obviously higher than 71. 05% of the control group（ P 〈 0. 05）. Conclusion The quadri- combinaiton eradication therapy in treating peptic ulcer patients with Helicobacter pylori has a remarkable effect with no adverse reaction phenomenon. Compared with the PPI and triple- commination therapy,the patients’ recovery rate is better,which is worthy of clinical promotion.
出处
《中国药业》
CAS
2015年第23期181-183,共3页
China Pharmaceuticals
关键词
消化性溃疡
幽门螺杆菌
枸橼酸铋钾
奥美拉唑
peptic ulcer
Helicobacter pylori
Colloidal Bismuth Subcitrate
omeprazole
